Ambroxol Acefyllinate

Summary

Ambroxol Acefyllinate (CHEMBL4297663) is a phase-3 clinical-stage small molecule; indicated across 1 condition including bronchial disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 616.3 Da · C22H28Br2N6O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297663
Name	Ambroxol Acefyllinate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	176595
Molecular formula	C22H28Br2N6O5
Molecular weight	616.3
InChIKey	IPUHJDQWESJTGD-UHFFFAOYSA-N

SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O.C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O

IUPAC name: 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid

Also known as: Acebrophylline, Ambromucil, Ambroxol acefyllinate, Ambroxol theophyllinate, Broncomnes, Surfolase, AMBROXOL ACEFYLLINATE

Patent coverage: 7 distinct patent families (18 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bronchial disorder	3	MONDO:0001358	EFO:1002018

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02792946	PHASE3	COMPLETED	Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis
NCT01723891	PHASE1	COMPLETED	Study To Compare Safety and Pharmacokinetic Properties of Surfolase Capsule and HT-002-01 in Healthy Male Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).